This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Small Cell Lung Cancer, Polygonal Type
and you are
over 18
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

The study will investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced epidermal growth factor receptor (EGFR)T790M positive advanced NSCLC patients. In addition, we will explore whether PD-L1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of PD due to osimertinib resistance.

Provided treatments

  • Other: No interventions will be taken in this Observational study

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03029858. The sponsor of the trial is Guangdong Association of Clinical Trials and it is looking for 155 volunteers for the current phase.
Official trial title:
Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients